فرآوردههای تزریقی ایران
دفرا | Stocks - Tehran Stock Exchange (TSE)
داروهای شیمیایی و گیاهی
Sector:
داروهای شیمیایی و گیاهی
Market Type:
Stocks
Status:
Authorized
Last Price: 51,320 2.99
Close Price: 51,150
Income Statement
AGM
Interim
2026/06/22 Fiscal Year 2026/03/2012 Month | 2025/06/23 Fiscal Year 2025/03/2012 Month | 2024/06/23 Fiscal Year 2024/03/1912 Month | ||
|---|---|---|---|---|
Revenue from Services & Sales | 31.445 Trillion | 14.531 Trillion | 10.742 Trillion | |
Total Revenues | 31.445 Trillion | 14.531 Trillion | 10.742 Trillion | |
Cost of Goods Sold | 8.579 Trillion | 4.207 Trillion | 3.329 Trillion | |
Gross Profit | 22.865 Trillion | 10.324 Trillion | 7.413 Trillion | |
General & Administrative Expenses | 951.523 Billion | 750.603 Billion | 419.686 Billion | |
Net Operating Income & Expenses | 210.618 Billion | 131.853 Billion | 91.127 Billion | |
Operating Profit (Loss) | 22.124 Trillion | 9.705 Trillion | 7.085 Trillion | |
Profit Before Tax | 22.908 Trillion | 9.941 Trillion | 7.663 Trillion | |
Tax | 3.791 Trillion | 1.375 Trillion | 1.591 Trillion | |
Net Profit (Loss) After Tax | 19.116 Trillion | 8.566 Trillion | 6.072 Trillion | |
Retained Earnings at Beginning of Period | 8.766 Trillion | 6.92 Trillion | 5.681 Trillion | |
Approved Dividends — Prior Year AGM | -4.312 Trillion | -5.18 Trillion | -4.76 Trillion | |
Capital Decrease (Increase) from Accumulated Losses (Retained Earnings) | -4.2 Trillion | -1.4 Trillion | - | |
Allocable Profit | 19.371 Trillion | 8.906 Trillion | 6.993 Trillion | |
Legal Reserve | 420 Billion | 140 Billion | - | |
Approved Dividends — Current Year | 10.85 Trillion | 4.312 Trillion | 5.18 Trillion | |
Retained Earnings at End of Period | 8.101 Trillion | 4.454 Trillion | 1.813 Trillion |